# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-month review on androgen deprivation with apalutamide, after radiotherapy to the prostate. **S**

## History of present illness

Mr. Neruda returns three months after starting treatment, with a professional Spanish interpreter. He finished 20 fractions of radiotherapy to the prostate three weeks ago. During the last two weeks of treatment he had more frequent urination and looser stools, and both are settling: he now gets up once a night, and his bowels are once or twice a day, with no bleeding. The rash he had five weeks ago faded within two weeks on the cream and cetirizine, and he has stopped both. The hip pain has gone; he has not taken acetaminophen for three weeks. Hot flashes come four or five times a day. His weight is up 2 kg, and he tires in the afternoons but still walks daily and writes every morning. He has had no falls. His home blood pressure readings have been around 130/80 since the amlodipine increase. He asks whether the treatment is working. **S**

| Element | Detail |
|---|---|
| Radiotherapy | 55 Gy in 20 fractions, finished three weeks ago |
| Urinary and bowel | Nocturia once; stools once or twice a day, settling; no bleeding |
| Rash | Resolved; triamcinolone and cetirizine stopped |
| Pain | None; acetaminophen stopped three weeks ago |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue; weight up 2 kg |
| Endocrine | Positive | Hot flashes four or five times a day; no cold intolerance or constipation |
| Genitourinary | Positive | Nocturia once; no burning or blood |
| Gastrointestinal | Positive | Softer stools once or twice a day, settling; no bleeding |
| Integumentary | Negative | Rash gone |
| Musculoskeletal | Negative | No bone pain |

6 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks **S**
- Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily **S**
- Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 94.2 kg; BMI 29.7 kg/m². All vital signs are synthetic.

PSA: 0.18 ng/mL; Total testosterone: 14 ng/dL (low); Hemoglobin: 12.9 g/dL (low); White cell count: 5.9 10*3/uL; Platelets: 231 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Glucose: 102 mg/dL (high); Creatinine: 0.99 mg/dL; eGFR (CKD-EPI 2021): 83 mL/min/1.73 m²; Calcium: 9.2 mg/dL; ALT: 24 U/L; AST: 22 U/L; Alkaline phosphatase: 96 U/L; Albumin: 4 g/dL; TSH: 5.4 mIU/L (high); Free T4: 1 ng/dL; Hemoglobin A1c: 6.1% (high); PHQ-2: 1; IPSS total (0 to 35): 9; Pain, 0 to 10: 1. All results are synthetic.

## Change since baseline

- PSA: 46.8 ng/mL (high) at baseline, 0.18 ng/mL at this visit **S**
- Total testosterone: 468 ng/dL at baseline, 14 ng/dL (low) at this visit **S**
- Hemoglobin: 13.6 g/dL at baseline, 12.9 g/dL (low) at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 5.9 10*3/uL at this visit **S**
- Platelets: 248 10*3/uL at baseline, 231 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 102 mg/dL (high) at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 0.99 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 87 mL/min/1.73 m² at baseline, 83 mL/min/1.73 m² at this visit **S**
- Calcium: 9.6 mg/dL at baseline, 9.2 mg/dL at this visit **S**
- ALT: 22 U/L at baseline, 24 U/L at this visit **S**
- AST: 24 U/L at baseline, 22 U/L at this visit **S**
- Alkaline phosphatase: 168 U/L (high) at baseline, 96 U/L at this visit **S**
- Albumin: 4.1 g/dL at baseline, 4 g/dL at this visit **S**
- Hemoglobin A1c: 5.9% (high) at baseline, 6.1% (high) at this visit **S**
- IPSS total (0 to 35): 17 at baseline, 9 at this visit **S**
- Pain, 0 to 10: 6 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 132/80 mm Hg; no ankle swelling |
| Neck | Thyroid not enlarged |
| Skin | No rash; mild darkening of the skin over the radiotherapy field |
| Neurological | Strength and sensation normal in both legs |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic hormone-sensitive prostate cancer, three months on treatment** (C61). Good response: PSA 0.18 ng/mL, at or below 0.2 ng/mL, which predicts a better outcome; testosterone 14 ng/dL; alkaline phosphatase back to normal at 96 U/L. Somatic testing of the biopsy found no alteration in the homologous recombination repair genes, and the tumor is microsatellite stable. **S**
   - Second leuprolide 22.5 mg injection today.
   - Continue apalutamide 240 mg daily.
   - PSA and testosterone every three months; imaging if PSA rises or new symptoms appear.
2. **After radiotherapy to the prostate** (Z92.3). Grade 1 urinary and bowel effects, settling. IPSS 9, down from 17 before treatment. **S**
   - Report blood in the urine or stool at any time.
3. **Raised TSH on apalutamide** (R94.6). TSH 5.4 mIU/L with free T4 1.0 ng/dL: subclinical, without symptoms of hypothyroidism. Raised TSH is common on apalutamide. **S**
   - Repeat TSH and free T4 with the lipid panel in about eight weeks; levothyroxine if free T4 falls or TSH rises above 10.
4. **Androgen deprivation with apalutamide** (Z79.899). Hemoglobin 12.9 g/dL, mildly low, as expected; hemoglobin A1c 6.1 percent, up from 5.9; weight up 2 kg; hot flashes four or five times a day. **S**
   - Walking and resistance exercise; fewer sweets at official dinners.
   - Lipids and the statin decision at the annual wellness visit in three weeks.
5. **Bone metastases** (C79.51). Pain resolved. **S**
   - Acetaminophen stopped.
6. **Apalutamide rash** (L27.0). Resolved without stopping apalutamide. **S**
   - No treatment needed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months | Completed today | 0.18 ng/mL at three months |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 14 ng/dL, castrate |
| Laboratory | Blood count | Periodically in metastatic disease | Completed today | Hemoglobin 12.9 g/dL (mildly low); white cells and platelets normal |
| Laboratory | Chemistry with calcium and alkaline phosphatase | Periodically on denosumab and in metastatic disease | Completed today | Calcium 9.2 mg/dL; creatinine 0.99 mg/dL; alkaline phosphatase 96 U/L, normal |
| Laboratory | TSH and free T4 on apalutamide | About every four months | Completed today | TSH 5.4 mIU/L (raised); free T4 1.0 ng/dL (normal) |
| Laboratory | Hemoglobin A1c | Baseline and yearly on androgen deprivation; repeated at three months for prediabetes | Completed today | 6.1 percent, up from 5.9 |
| Laboratory | Lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline at the first visit; statin decision at the annual wellness visit |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline three months ago |
| Imaging | Restaging imaging | If PSA rises or symptoms appear | Not indicated | PSA 0.18 ng/mL and no symptoms |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 132/80 mm Hg on amlodipine 10 mg; home readings about 130/80 |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 1 of 10 |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit, particularly after radiotherapy | Completed today | IPSS 9, down from 17 |
| Survey | Bowel function after radiotherapy | Every visit after radiotherapy | Completed today | Softer stools once or twice a day, settling; no bleeding |
| Survey | Sexual function | Periodically on androgen deprivation | Completed today | Lower libido and erections, as expected; no treatment wanted now |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit in three weeks |
| Medication safety | Rash on apalutamide | Every visit on androgen deprivation | Completed today | Resolved |
| Medication safety | Falls on apalutamide | Every visit on androgen deprivation | Completed today | No falls |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Hot flashes four or five times a day; afternoon fatigue; no medicine wanted yet |
| Medication safety | Second leuprolide injection | Every twelve weeks | Completed today | Given today |
| Referral | Somatic tumor testing result | Once | Completed today | No homologous recombination repair alteration; microsatellite stable |
| Self-management | Physical activity, weight and calcium intake | Every visit | Completed today | Walking daily; resistance exercise twice a week; calcium from food |

## Goal progress

- Diagnosis, staging and a shared treatment decision within three weeks of the first visit. Outcome by 2026-06-15: Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake. **S**
- Bone pain controlled, with a pain score of 2 or less and sleep restored. Outcome by 2026-07-13: Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation. **S**
- PSA of 0.2 ng/mL or less within about seven months of starting treatment. Outcome by 2026-09-14: PSA 46.8 to 0.18 ng/mL at three months. **S**
- Blood pressure below 130/80 mm Hg on androgen deprivation. In progress; target 2026-10-05. **S**
- Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk. In progress; target 2026-10-05. **S**
- Keep his morning writing and his official duties through treatment. In progress; target 2026-10-05. **S**

## Medication changes

- Stopped: Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026), American Urological Association and Society of Urologic Oncology
- ERLEADA (apalutamide) tablets: prescribing information (2026), Janssen Products, LP, via DailyMed (National Library of Medicine)
- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in three weeks. TSH and free T4 in about eight weeks. Medical oncology and the third leuprolide injection in twelve weeks, with PSA and testosterone. Denosumab again in four months. **S**
- Next scheduled visit 2026-10-05: subsequent annual wellness visit. **S**
